ARTICLE | Company News
Stallergenes, Ares Life Sciences inflammation news
February 28, 2011 8:00 AM UTC
Investment firm Ares re-opened its mandated offer in compliance with European law for the remaining stake of Stallergenes it does not own for €59 per share, or €424.5 million ($581.5 million). The pri...